Cocrystal receives approval from HREC for Phase I trial

Committee (HREC) to initiate a Phase I trial of CDI-988 for the treatment of Covid-19.

CDI-988 is an oral, broad-spectrum 3CL protease inhibitor designed using Cocrystal’s proprietary drug discovery platform technology.

The double-blind, randomised, dose-escalating, placebo-controlled study aims to to evaluate CDI-988’s tolerability, safety, and pharmacokinetics in healthy volunteers.

In August last year, Cocrystal Pharma selected hVIVO as a contract research organisation to conduct a Phase IIa human challenge trial of its oral antiviral candidate, CC-42344, for Influenza A.

hVIVO plc (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials, providing end-to-end early clinical development services for its broad and long-standing client base of biopharma companies.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    X
    LinkedIn
    hVIVO plc

    More articles like this

    hVIVO plc

    hVIVO fast-tracks drug trials and draws big pharma in

    In a sector where timelines can stretch over decades and budgets run into billions, hVIVO is rewriting the rules—delivering clinical insight in a fraction of the time and attracting heavyweight pharmaceutical partners along the way. hVIVO